Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AERINASDAQ:BCRXNASDAQ:IBRXNASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAERIAerie Pharmaceuticals$15.25$15.23$4.81▼$15.37$753.61M-0.06974,748 shs600 shsBCRXBioCryst Pharmaceuticals$10.18-1.9%$9.37$5.92▼$11.31$2.13B1.113.96 million shs876,661 shsIBRXImmunityBio$3.13+1.8%$2.63$1.83▼$7.63$2.76B0.146.04 million shs3.72 million shsIMVTImmunovant$15.61-0.3%$14.95$12.72▼$34.47$2.67B0.611.53 million shs491,018 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAERIAerie Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCRXBioCryst Pharmaceuticals0.00%-6.07%+1.27%+33.98%+68.07%IBRXImmunityBio0.00%-2.54%+8.10%+5.50%-48.49%IMVTImmunovant0.00%-6.62%+8.30%-21.78%-39.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAERIAerie PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCRXBioCryst Pharmaceuticals4.4199 of 5 stars4.41.00.04.23.41.70.6IBRXImmunityBio2.6786 of 5 stars3.62.00.00.03.31.70.6IMVTImmunovant1.3735 of 5 stars3.50.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAERIAerie Pharmaceuticals 0.00N/AN/AN/ABCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5662.71% UpsideIBRXImmunityBio 3.20Buy$12.25292.00% UpsideIMVTImmunovant 2.90Moderate Buy$38.33145.57% UpsideCurrent Analyst Ratings BreakdownLatest AERI, IBRX, IMVT, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/28/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAERIAerie Pharmaceuticals$194.13M3.88N/AN/A($3.32) per share-4.59BCRXBioCryst Pharmaceuticals$503.49M4.23N/AN/A($2.22) per share-4.58IBRXImmunityBio$31.22M88.34N/AN/A($0.88) per share-3.55IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAERIAerie Pharmaceuticals-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/ABCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)IBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)IMVTImmunovant-$259.34M-$2.74N/AN/AN/AN/A-77.94%-69.82%8/5/2025 (Estimated)Latest AERI, IBRX, IMVT, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAERIAerie PharmaceuticalsN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAERIAerie PharmaceuticalsN/A2.271.92BCRXBioCryst PharmaceuticalsN/A2.782.73IBRXImmunityBioN/A2.682.64IMVTImmunovantN/A6.046.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAERIAerie Pharmaceuticals95.94%BCRXBioCryst Pharmaceuticals85.88%IBRXImmunityBio8.58%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAERIAerie Pharmaceuticals4.44%BCRXBioCryst Pharmaceuticals4.80%IBRXImmunityBio76.79%IMVTImmunovant5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAERIAerie Pharmaceuticals37649.42 million47.22 millionOptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableIMVTImmunovant120170.92 million159.84 millionOptionableAERI, IBRX, IMVT, and BCRX HeadlinesRecent News About These CompaniesImmunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13 at 2:06 PM | seekingalpha.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts Immunovant FY2027 EarningsJune 12, 2025 | americanbankingnews.comBrokers Set Expectations for Immunovant FY2027 EarningsJune 10, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Down 4.7% - Here's WhyJune 9, 2025 | marketbeat.comImmunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?June 2, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.92 Million Stock Position in Immunovant, Inc. (NASDAQ:IMVT)June 2, 2025 | marketbeat.comHC Wainwright Estimates Immunovant FY2030 EarningsJune 2, 2025 | marketbeat.comLeerink Partnrs Estimates Immunovant FY2030 EarningsJune 2, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Gap Up on Earnings BeatMay 30, 2025 | marketbeat.comIMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in FocusMay 30, 2025 | zacks.comImmunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Expectations By $0.08 EPSMay 30, 2025 | marketbeat.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 30, 2025 | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29, 2025 | msn.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025May 29, 2025 | globenewswire.comImmunovant (IMVT) to Release Earnings on WednesdayMay 29, 2025 | marketbeat.comH.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) StockMay 28, 2025 | msn.comNuveen Asset Management LLC Sells 189,759 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 26, 2025 | marketbeat.comBank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 26, 2025 | marketbeat.comWoodline Partners LP Sells 772,251 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 24, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LPMay 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAERI, IBRX, IMVT, and BCRX Company DescriptionsAerie Pharmaceuticals NASDAQ:AERIAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.BioCryst Pharmaceuticals NASDAQ:BCRX$10.18 -0.20 (-1.88%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.ImmunityBio NASDAQ:IBRX$3.12 +0.06 (+1.79%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$15.61 -0.05 (-0.32%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
